Published in Arch Dis Child on April 01, 1996
Parental and professional perception of need for emergency admission to hospital: prospective questionnaire based study. Arch Dis Child (1998) 2.45
Planning for the future: the experience of implementing a children's day assessment unit in a district general hospital. Arch Dis Child (1997) 1.83
Hospital based alternatives to acute paediatric admission: a systematic review. Arch Dis Child (2005) 1.73
Ambulatory paediatrics--making a difference. Arch Dis Child (1997) 1.41
Unscheduled return visits within 72 hours to an assessment unit. Arch Dis Child (1999) 1.00
A seven year experience of medical emergencies in the assessment unit. Arch Dis Child (2003) 0.81
Evaluation of a protocol for selective empiric treatment of fever without localising signs. Arch Dis Child (1997) 0.80
Setting up a Paediatric Rapid Access Outpatient Unit: views of general practice teams. BMC Fam Pract (2008) 0.79
Review of a paediatric emergency department observation unit. Emerg Med J (2006) 0.75
How long do we need to observe head injuries in hospital? Arch Dis Child (1984) 3.05
Paediatric accident & emergency short-stay ward: a 1-year audit. Arch Emerg Med (1993) 1.81
Treatment of acute asthmatic attacks in a holding unit of a pediatric emergency room. Ann Allergy (1980) 1.13
Hepatocellular carcinoma in a noncirrhotic infant after prolonged parenteral nutrition. J Pediatr (1985) 1.10
Can short hospital admissions be avoided? A review of admissions of less than 24 hours' duration in a paediatric teaching hospital. Med J Aust (1991) 1.10
Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet (2000) 8.10
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol (1998) 3.65
Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol (1990) 3.31
Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet (1996) 3.17
Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest (1998) 2.97
HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A (1991) 2.83
Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology (1997) 2.61
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med (1994) 2.18
Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest (1991) 2.08
T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology (1994) 2.00
Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology (2001) 1.99
Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B. J Immunol (1987) 1.85
Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J Virol (1993) 1.74
Functional characterization of cloned intrahepatic, hepatitis B virus nucleoprotein-specific helper T cell lines. J Immunol (1987) 1.25
Selective sensitization of peripheral blood T lymphocytes to hepatitis B core antigen in patients with chronic active hepatitis type B. Clin Exp Immunol (1986) 1.14
Cellular immune response to hepatitis B virus antigens. An overview. J Hepatol (1988) 1.05
Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: interaction with HLA and T-cell receptor. Hepatology (1997) 1.04
The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man. J Clin Invest (1989) 1.02
Identification of immunodominant hepatitis C virus (HCV)-specific cytotoxic T-cell epitopes by stimulation with endogenously synthesized HCV antigens. Hepatology (2001) 0.99
Parasitic diatoms inside antarctic sponges. Biol Bull (2000) 0.97
Immunopathogenesis of hepatitis C virus infection. J Hepatol (1999) 0.97
Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. Br J Anaesth (2010) 0.96
Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen. Gastroenterology (1992) 0.95
Gonadotropin-releasing hormone action in the pituitary: a three step mechanism. Endocr Rev (1981) 0.93
Performance evaluation of paediatric propofol pharmacokinetic models in healthy young children. Br J Anaesth (2011) 0.93
Antiviral cell-mediated immune responses during hepatitis B and hepatitis C virus infections. Recent Results Cancer Res (1998) 0.92
Autopresentation of hepatitis B virus envelope antigens by T cells. J Virol (1992) 0.86
Detection and quantification of Prymnesium parvum (Haptophyceae) by real-time PCR. Lett Appl Microbiol (2007) 0.84
Inappropriate Halsted mastectomy and patient volume in Italian hospitals. Am J Public Health (1993) 0.83
Effectiveness of different therapeutic strategies in preventing diverticulitis recurrence. Eur Rev Med Pharmacol Sci (2013) 0.83
Physicians' view of practice guidelines. A survey of Italian physicians. Soc Sci Med (1996) 0.81
The influence of patient characteristics on the appropriateness of surgical treatment for breast cancer patients. Progetto Oncologia Femminile. Ann Oncol (1993) 0.81
Cell mediated immune response to hepatitis B virus nucleocapsid antigen. Arch Virol Suppl (1993) 0.80
Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoral and endothelial cells and tumor-infiltrating macrophages. Immunopharmacol Immunotoxicol (2005) 0.80
New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease. Immunopharmacol Immunotoxicol (2006) 0.80
Functional modulation of hepatitis B core antigen-specific T lymphocytes by an autoreactive T cell clone. J Immunol (1988) 0.78
Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice. Eur Rev Med Pharmacol Sci (2010) 0.78
Capture probe conjugated to paramagnetic nanoparticles for purification of Alexandrium species (Dinophyceae) DNA from environmental samples. J Appl Microbiol (2006) 0.78
Variation in use of breast surgery and characteristics of hospitals' surgical staff. Int J Qual Health Care (1994) 0.78
Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice? Aliment Pharmacol Ther (2013) 0.77
PreS antigen expression and anti-preS response in hepatitis B virus infections: relationship to serum HBV-DNA, intrahepatic HBcAg, liver damage and specific T-cell response. Arch Virol Suppl (1992) 0.76
Study on the oligosaccharides composition of the water-soluble fraction of marine mucilage by electrospray tandem mass spectrometry. Water Res (2007) 0.76
[Correlations between trophism of the external genitalia and hormone levels during menopausal age]. Ann Ostet Ginecol Med Perinat (1991) 0.75
[The effect of ursodeoxycholic acid in patients with liver cirrhosis and chronic hypertransaminasemia]. Minerva Gastroenterol Dietol (1994) 0.75
Immune pathogenesis of hepatitis B. Arch Virol Suppl (1992) 0.75
Crohn's appendicitis. Endoscopy (2010) 0.75
Clinical features of hepatitis delta virus infection in a northern Italian area. Infection (1988) 0.75
[A case of myocardial infarct caused by coronaritis]. Minerva Med (1982) 0.75
[Diuretics in cardiovascular pathology. Their clinical use in the light of recent pathogenetic studies]. Minerva Med (1984) 0.75
[Uses, role and limitations of computerized tomography (CT) in mediastinal and cardiac diagnostics and the prospects of use of new related methods]. Clin Ter (1984) 0.75
[Electrocardiographic findings in a group of treated with mitral commissurotomy]. Boll Soc Ital Cardiol (1966) 0.75
Therapeutic organizer (TH.OR.): a new tool in critical patient management. Cardiovasc Drugs Ther (1999) 0.75
[Radiological findings in a group of subjects treated with mitral commissurotomy]. Boll Soc Ital Cardiol (1966) 0.75
[The adjuvant treatment of operable breast carcinoma. The current status and outlook]. Recenti Prog Med (1993) 0.75
[Promoting the improvement of clinical practice: guidelines]. Epidemiol Prev (1994) 0.75
[Effects of Tettuccio water from the Montecatini spa on chronic constipation: clinical evaluation and study of intestinal motor activity]. Clin Ter (1984) 0.75
[Gastric acidometry schistosomal in portal hypertension]. Rev Bras Malariol Doencas Trop (1968) 0.75
[The immunopathogenesis of hepatitis B]. Ann Ital Med Int (1993) 0.75
[Tetrabiguanide: hematic and urinary concentrations in humans]. Boll Soc Ital Biol Sper (1967) 0.75
[Climacteric symptomatology: relation with hormone levels and trophic features of the external genitalia]. Ann Ostet Ginecol Med Perinat (1992) 0.75